Background {#section1-1076029617739702}
==========

The superior cavopulmonary anastomosis (SCPA) procedure represents the second step of the 3-staged palliative strategy for patients with single-ventricle physiology and involves redirecting deoxygenated blood directly from the superior vena cava (SVC) to the pulmonary artery (PA), bypassing the heart and effectively limiting ventricular workload exclusively to systemic circulation output.^[@bibr1-1076029617739702]^

Superior cavopulmonary anastomosis is typically achieved with 1 of 2 approaches: the bidirectional Glenn (BDG) and the hemi-Fontan. The classical BDG procedure consists of division of the SVC from the right atrium (RA), an incision made on the PA, and suturing of the SVC to the RA incision, creating an end-to-side SVC-PA anastomosis.^[@bibr2-1076029617739702]^ In contrast, the hemi-Fontan procedure preserves the SVC-RA confluence, creating an anastomosis between the SVC-RA confluence and the central and branch PAs in an end-to-end fashion.^[@bibr3-1076029617739702]^

Thrombotic and thromboembolic complications represent important considerations in the postoperative management of these patients. While thrombotic complications have been noted to be infrequent postoperatively, many patients proceed to the Fontan procedure, suggesting there may be a role for thromboprophylaxis in the routine management of these patients to increase the likelihood of successful conversion.^[@bibr4-1076029617739702]^ Recommendations from the *American College of Chest Physicians Evidence-Based Clinical Practice Guidelines for Antithrombotic Therapy and the Prevention of Thrombosis* (9th ed) encourage the use of postoperative unfractionated heparin (UFH) for neonates and children (grade 2C).^[@bibr4-1076029617739702]^ Summarized recent data regarding postoperative thromboprophylaxis protocols and risks of thrombosis, thromboembolism, and mortality remain limited. To the best of our knowledge, no randomized controlled trials comparing thromboprophylaxis strategies have been published.

The purpose of this literature review is (1) to estimate the risk of thrombosis and thromboembolism associated with the SCPA procedure and (b) to examine current thromboprophylaxis regimens utilized and their effectiveness in reducing thrombosis and thromboembolic risks. This is the third in a series of 3 literature reviews evaluating risk of thrombosis and thromboembolism and postoperative thromboprophylactic protocols in use with each stage of the 3-stage palliative procedure for hypoplastic left heart syndrome patients.^[@bibr5-1076029617739702],[@bibr6-1076029617739702]^

Methods {#section2-1076029617739702}
=======

Data Sources and Searches {#section3-1076029617739702}
-------------------------

We searched the central MEDLINE and EMBASE (to August 2017). We restricted the search to humans and infants and children. A detailed search strategy for both MEDLINE and EMBASE, developed and conducted with the help of a librarian (P.L.), is provided in [Appendix A](#app1-1076029617739702){ref-type="app"}.

After the removal of identifiable duplicate hits, pairs of 2 investigators (N.B. and A.Y.) independently screened each title and abstract retrieved from the search. Consensus was reached on decisions to include or exclude potentially eligible studies, with discrepancies resolved by discussion between the 2 reviewers and adjudication by a third reviewer (A.A.) to make the final decision on study eligibility for full-text review as necessary. For all eligible titles and abstracts, full-text articles were retrieved for detailed review and were independently screened in duplicate (N.B. and A.Y.), with discrepancies resolved by discussion and adjudication by a third reviewer (A.A.) as necessary. Relevant data were then extracted from eligible studies as per a predetermined data extraction form ([Appendix B](#app2-1076029617739702){ref-type="app"}). Reference lists of eligible systematic reviews were screened by a reviewer to identify potentially eligible studies.

Study Eligibility {#section4-1076029617739702}
-----------------

We included all prospective or retrospective cohort studies that included neonates, infants, or children undergoing 1 or more variants of the SCPA procedure. Articles were considered eligible if they met the following criteria: (1) prospective or retrospective cohort study design or a systematic review of such studies, (2) involved a pediatric population undergoing either (or both) of the BDG or hemi-Fontan procedures, and (c) explicit reporting of outcomes related to thrombotic or thromboembolic events. We excluded clinical trials, case reports and case series, narrative reviews, and other secondary study designs and studies that did not make explicit mention of the primary outcomes of interest in the abstract. Studies exclusively including cases with thrombotic events and thromboembolic events were excluded. Studies reporting outcomes for interventions subsequent to SCPA operation with no explicit reporting of outcomes related to SCPA were excluded.

Data Abstraction {#section5-1076029617739702}
----------------

We abstracted the following information from each eligible study: sample size; period of data collection; description of procedure; patient age, sex, weight, relevant comorbidities, or complications; prophylaxis type, dose, frequency and duration, and proportion of patients receiving prophylaxis; duration of follow-up (days); thrombotic events (primary outcome) reported or not reported, definition of outcome, number of patients with events, and number of patients evaluated; thromboembolic events (primary outcome) reported or not reported, definition of outcome, number of patients with events, and number of patients evaluated; and mortality (secondary outcome) incidence, number of deaths, and number of patients evaluated.

The Newcastle-Ottawa Scale (NOS) for cohort studies was considered for evaluation of risk of bias. However, given studies generally included a single cohort where SCPA was the exposure and baseline assessments for thrombosis and embolisms were not conducted, the NOS' criteria related to nonexposed cohort selection, ascertainment of exposure, demonstration of outcomes of interest not being present at baseline, and cohort comparability were deemed not applicable. As such, formal judgments regarding risk of bias were not conducted.

Data Synthesis {#section6-1076029617739702}
--------------

Studies were stratified by type of prophylaxis provided and further by type of procedure. Data were presented as proportions for the outcomes of interest for each study independently and were synthesized qualitatively without a meta-analysis.

Results {#section7-1076029617739702}
=======

Of all, 1303 unique references were identified between Ovid MEDLINE and EMBASE searches using our search strategy ([Appendix A](#app1-1076029617739702){ref-type="app"}). Of these, 34 were considered potentially eligible following title and abstract review, and 13 fulfilled eligibility criteria and were included in our literature review following full-text review.^[@bibr7-1076029617739702][@bibr8-1076029617739702][@bibr9-1076029617739702][@bibr10-1076029617739702][@bibr11-1076029617739702][@bibr12-1076029617739702][@bibr13-1076029617739702][@bibr14-1076029617739702][@bibr15-1076029617739702][@bibr16-1076029617739702][@bibr17-1076029617739702][@bibr18-1076029617739702]--[@bibr19-1076029617739702]^ No additional eligible studies were identified with a review of the reference lists of included studies from the search ([Figure 1](#fig1-1076029617739702){ref-type="fig"}).

![Study flowchart.](10.1177_1076029617739702-fig1){#fig1-1076029617739702}

Study Characteristics {#section8-1076029617739702}
---------------------

A total of 1136 patients (375 males, 237 females, 524 not reported) were included across the 13 eligible studies, 4 (30.8%) of which included over 100 patients. Eight (61.5%) studies included patients who underwent the BDG procedure; 9 (69.2%) studies included patients who underwent the hemi-Fontan procedure. The primary indication for operation for the majority of included patients was hypoplastic left heart syndrome. Six (46.2%) studies were conducted in the United States, 2 (15.4%) studies were conducted in each of Canada and Germany, and 1 (7.7%) study was conducted in each of Poland, Japan, and China ([Table 1](#table1-1076029617739702){ref-type="table"}).

###### 

Characteristics of Included Studies.

![](10.1177_1076029617739702-table1)

  Author                                          Year   Country         Sample Size                        Procedure                                                                        Recruitment    Age, Mean (SD), months                            Male/Female                                Weight, Mean (SD), kg                                      Cardiac Conditions and Comorbidities
  ----------------------------------------------- ------ --------------- ---------------------------------- -------------------------------------------------------------------------------- -------------- ------------------------------------------------- ------------------------------------------ ---------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------
  Douville et al^[@bibr7-1076029617739702]\ ,a^   1991   United States   14                                 Hemi-Fontan                                                                      1989-1991      9 (6-69)^b^                                       --                                         --                                                         --
  Bradley et al^[@bibr8-1076029617739702]\ ,a^    1996   United States   85                                 BDG (n = 33), BDG with intra-atrial patch (n = 14),^a^ hemi-Fontan (n = 38)^a^   1990-1995      4.8 (1.4)                                         56/29                                      5.6 (1.0)                                                  --
  Chun et al^[@bibr9-1076029617739702]^           2004   United States   71                                 Hemi-Fontan                                                                      1988-2000      --                                                --                                         --                                                         --
  Day et al^[@bibr10-1076029617739702]\ ,a^       2006   United States   177                                BDG                                                                              1984-2004      17.3 (2.2)^b,c^                                   87/90                                      --                                                         --
  Procelewska et al^[@bibr11-1076029617739702]^   2007   Poland          43                                 Hemi-Fontan                                                                      2003-2005      5.9 (3.1)                                         --                                         6.0 (1.5)                                                  --
  Honjo et al^[@bibr12-1076029617739702]^         2010   Canada          61                                 BDG/hemi-Fontan^d^                                                               1990-2007^d^   BDG: 11.4^b,d^; V-shaped/hemi- Fontan: 7.2^b,d^   --                                         BDG: 11.7 (11.8)^d^; V-shaped/hemi- Fontan: 6.5 (2.5)^d^   --
  Hansen et al^[@bibr13-1076029617739702]\ ,a^    2011   Germany         119                                Hemi-Fontan (n = 113), Bilateral BDG (n = 6)^a^                                  1996-2007      5.1 (4.4)^a^                                      80/39                                      5.5 (1.2)                                                  --
  Manlhiot et al^[@bibr14-1076029617739702]^      2012   Canada          139                                BDG                                                                              2003-2008      28 (13-44)^d^                                     88/51                                      --                                                         --
  Hansen et al^[@bibr15-1076029617739702]\ ,a^    2013   Germany         32                                 Hemi-Fontan^a^                                                                   2009-2011      3.6 (2.0)^a^                                      22/10^a^                                   5.3 (1.0)                                                  HLHS: n = 26, Mitral atresia: n = 2, corrected TGA: n = 1, double inlet LV: n = 1, double outlet RV: n = 1, critical aortic stenosis: n = 1
  Zampi et al^[@bibr16-1076029617739702]\ ,a^     2013   United States   244                                Hemi-Fontan                                                                      2006-2011      --                                                --                                         --                                                         --
  Ando et al^[@bibr17-1076029617739702]\ ,a^      2014   Japan           40 (27 unilateral, 13 bilateral)   BDG                                                                              2004-2011      Unilateral: 18.8 (11.8); bilateral: 11.1 (3.8)    Unilateral: 17/10^a^; bilateral: 10/3^a^   Unilateral: 8.5 (2.3); bilateral: 7.8 (1.3)                --
  Ji et al^[@bibr18-1076029617739702]^            2014   China           20                                 BDG^d^                                                                           2011-2012      50.4 (19.2)^e^                                    15/5                                       15.4 (3.7)^e^                                              --
  Zahr et al^[@bibr19-1076029617739702]^          2016   United States   91                                 Hemi-Fontan (n = 89), BDG (n = 2)                                                1958-1988      6.6 (2.5)                                         --                                         --                                                         Tricuspid atresia: n = 33, TOF: n = 15, TGA/VSD/PS: n = 19, PA: n = 5, complex SV: n = 15, Ebstein: n = 4

Abbreviations: BDG, bidirectional Glenn; HLHS, hypoplastic left heart syndrome; LV, left ventricle; RV, right ventricle; PS, pulmonary stenosis, SV , single ventricle; SD, standard deviation; VSD, ventricular septal defect; TOF, Tetralogy of Fallot; TGA, transposition of great arteries.

^a^Study authors confirmed accuracy of the extracted data and provided additional data where applicable.

^b^Age reported as median (range).

^c^Age reported as mean (standard error of the mean).

^d^From 1990 to 1999, 37 patients underwent conventional anastomosis with limited postoperative anticoagulation. From 1999 to 2007, 24 patients underwent a V-shaped anastomosis or hemi-Fontan with routine postoperative anticoagulation.

^e^At time of angiography, not at time of surgery.

Among the 13 eligible studies, 5 (38.5%) studies^[@bibr10-1076029617739702],[@bibr11-1076029617739702],[@bibr14-1076029617739702],[@bibr16-1076029617739702],[@bibr17-1076029617739702]^ reported on postoperative UFH, warfarin, low-molecular-weight heparin (LMWH), or acetylsalicylic acid (ASA) use alone; 4 (30.8%) studies^[@bibr8-1076029617739702],[@bibr12-1076029617739702],[@bibr13-1076029617739702],[@bibr15-1076029617739702]^ reported on combination UFH and ASA; 1 (7.7%) study^[@bibr9-1076029617739702]^ reported on combination ASA and warfarin; 1 (7.7%) study^[@bibr14-1076029617739702]^ reported on combination ASA and LMWH; 2 (15.4%) studies^[@bibr12-1076029617739702],[@bibr16-1076029617739702]^ reported on combination UFH and LMWH; and 4 (30.8%) studies^[@bibr8-1076029617739702],[@bibr12-1076029617739702],[@bibr14-1076029617739702],[@bibr19-1076029617739702]^ reported on a no-thromboprophylaxis protocol postoperatively.

Of note, Bradley et al initially followed a no-thromboprophylaxis protocol, subsequently introducing an UFH-ASA protocol.^[@bibr8-1076029617739702]^ Manlhiot et al followed different prophylactic protocols based on patient-related and operative characteristics; individual thrombotic and thromboembolic event data were not reported for each prophylactic protocol; as such, study findings were summarized separately from other included studies.^[@bibr14-1076029617739702]^ Two (15.4%) studies^[@bibr7-1076029617739702],[@bibr18-1076029617739702]^ did not explicitly report a thromboprophylaxis regimen ([Table 2](#table2-1076029617739702){ref-type="table"}).

###### 

Prophylaxis Strategies Across Included Studies.

![](10.1177_1076029617739702-table2)

  Author                                          Year   Portion of Sample Receiving TPx       Prophylaxis Type                                                                                                                                       Prophylaxis Dose                                                                            Prophylaxis Duration
  ----------------------------------------------- ------ ------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------ ------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------
  Douville et al^[@bibr7-1076029617739702]\ ,a^   1991   \-                                    \-                                                                                                                                                     \-                                                                                          \-
  Bradley et al^[@bibr8-1076029617739702]\ ,a^    1996   49.4%^a,b^                            Prior to PE events: none (n = 43)^a,b^; following PE events: heparin and ASA (n = 42)^a,b^                                                             \-                                                                                          \-
  Chun et al^[@bibr9-1076029617739702]^           2004   \-                                    ASA and warfarin                                                                                                                                       \-                                                                                          \-
  Day et al^[@bibr10-1076029617739702]\ ,a^       2006   \-                                    Warfarin^c^                                                                                                                                            \-                                                                                          \-
  Procelewska et al^[@bibr11-1076029617739702]^   2007   100%                                  ASA                                                                                                                                                    2 to 5 mg/kg/d                                                                              \-
  Honjo et al^[@bibr12-1076029617739702]^         2010   BDG: 0%; V-shaped/hemi-Fontan: 100%   BDG: None^d^; V-shaped/hemi-Fontan: LMWH (85%) or ASA (15%)^d^                                                                                         Initial UFH (dose unspecified) LMWH: 1 mg/kg/d, ASA: (NR)                                   \-
  Hansen et al^[@bibr13-1076029617739702],a^      2011   \-                                    Initial heparin, followed by ASA^a,e^                                                                                                                  Heparin: 100 IU/kg/d^a^; ASA: 3 mg/kg/d^a^                                                  Heparin: until central lines removed^a^; ASA: lifelong^a^
  Manlhiot et al^[@bibr14-1076029617739702]^      2012   46%^f^                                Different strategies: None, ASA only, ASA + enoxaparin, enoxaparin only, or warfarin.^f^ For bilateral BDG shunts and high-risk cases: enoxaparin^g^   Enoxaparin: 1.5 mg/kg/d for age \<2 months, 1.0 mg/kg/d for noninfants; Other types: (NR)   For patients with bilateral BDG shunts: up to Fontan procedure. For high-risk patients: within 3 months^g^
  Hansen et al^[@bibr15-1076029617739702],a^      2013   \-                                    Initial heparin, followed by ASA^a,e^                                                                                                                  Heparin: 100 IU/kg/d^a^; ASA: 3 mg/kg/d^a^                                                  Heparin: until central lines removed^a^; ASA: lifelong^a^
  Zampi et al^[@bibr16-1076029617739702]\ ,a^     2013   100%                                  ASA (n = 244), heparin (pts with known clot or low flow state), heparin bridged to enoxaparin (pts with femoral venous or arterial occlusion)          \-                                                                                          \-
  Ando et al^[@bibr17-1076029617739702]\ ,a^      2014   Unilateral: 96%, bilateral: 92%       Unilateral: heparin (n = 9), warfarin (n = 15), ASA (n = 26). Bilateral: heparin (n = 6), warfarin (n = 6), ASA (n = 12)                               Heparin: 200-400 U/kg/d, ASA: 1 mg/kg/d, Warfarin: for INR of 1.5                           Heparin: until beginning of oral feeding^a^
  Ji et al^[@bibr18-1076029617739702]^            2014   \-                                    \-                                                                                                                                                     \-                                                                                          \-
  Zahr et al^[@bibr19-1076029617739702]^          2016   0%                                    None                                                                                                                                                   \-                                                                                          \-

Abbreviations: ASA, acetylsalicylic acid; BDG, bidirectional Glenn; INR, international normalized ratio; LMWH, low-molecular-weight heparin; NR, not reported; PE, pulmonary embolism; TPx, thromboprophylaxis; UFN, unfractionated heparin.

^a^Study authors confirmed accuracy of the extracted data and provided additional data where applicable.

^b^This prophylaxis was only instituted after 3 episodes of pulmonary artery thrombosis had occurred and was only used in 42 patients.

^c^Unclear if warfarin was used in this study.

^d^From 1990 to 1999, 37 patients underwent conventional anastomosis with limited postoperative anticoagulation. From 1999 to 2007, 24 patients underwent a V-shaped anastomosis or hemi-Fontan with routine postoperative anticoagulation.

^e^Hansen 2011 and 2013: ASA 3 mg/kg/d was initiated from postoperative days 1 or 2, together with oral feeds.

^f^Manlhiot 2012: no prophylaxis: n = 75 (54.0%); ASA only: n = 9 (6.5%); ASA + enoxaparin: n = 5 (3.6%); enoxaparin only: n = 48 (34.5%); warfarin only: n = 2 (1.4%).

^g^Manlhiot 2012: high-risk cases were defined as patients with previous thrombotic complications.

Thromboprophylaxis Protocols and Postoperative Outcomes {#section9-1076029617739702}
-------------------------------------------------------

Overall, incidence of thrombotic and thromboembolic events ranged from 0% to 28.0% and 0% to 12.5%, respectively. Three studies reported rates of major bleeding or bleeding requiring reintervention, ranging from 0% to 2.9%.^[@bibr10-1076029617739702],[@bibr17-1076029617739702],[@bibr20-1076029617739702]^ Mortality rates ranged from 2.5% to 50.5%.

Incidence of thrombotic events ranged from 0% to 1.2% for single-agent prophylaxis (2 studies),^[@bibr16-1076029617739702],[@bibr17-1076029617739702]^ 4.2% for UFH-ASA (1 study),^[@bibr13-1076029617739702]^ 0% for warfarin-ASA (1 study),^[@bibr9-1076029617739702]^ 1.2% for UFH-LMWH (1 study),^[@bibr16-1076029617739702]^ 0% for no prophylaxis (1 study),^[@bibr19-1076029617739702]^ and 5.0% to 7.1% for no explicitly-reported thromboprophylaxis protocol (2 studies).^[@bibr7-1076029617739702],[@bibr18-1076029617739702]^

Incidence of thromboembolic events ranged from 0% to 2.9% for single-agent prophylaxis (4 studies),^[@bibr10-1076029617739702],[@bibr11-1076029617739702],[@bibr14-1076029617739702],[@bibr17-1076029617739702]^ 0% to 12.5% for UFH-ASA (4 studies),^[@bibr8-1076029617739702],[@bibr12-1076029617739702],[@bibr13-1076029617739702],[@bibr15-1076029617739702]^ 5.6% for warfarin-ASA (1 study),^[@bibr9-1076029617739702]^ 4.2% for UFH-LMWH (1 study),^[@bibr12-1076029617739702]^ 2.2% to 8.1% for no prophylaxis (3 studies),^[@bibr8-1076029617739702],[@bibr12-1076029617739702],[@bibr19-1076029617739702]^ and 7.1% for no explicitly-reported thromboprophylaxis protocol (1 study).^[@bibr7-1076029617739702]^

Reported mortality rates ranged from 2.5% to 7.9% for single-agent prophylaxis (3 studies),^[@bibr10-1076029617739702],[@bibr14-1076029617739702],[@bibr17-1076029617739702]^ 3.1% to 12.5% for UFH-ASA (4 studies),^[@bibr8-1076029617739702],[@bibr12-1076029617739702],[@bibr13-1076029617739702],[@bibr15-1076029617739702]^ 12.5% for UFH-LMWH (1 study),^[@bibr12-1076029617739702]^ 7.9% to 50.5% for no prophylaxis (3 studies),^[@bibr8-1076029617739702],[@bibr12-1076029617739702],[@bibr19-1076029617739702]^ and 7.1% for no explicitly-reported thromboprophylaxis protocol (1 study).^[@bibr7-1076029617739702]^

Manlhiot et al applied a protocol involving several thromboprophylaxis protocols: no prophylaxis (54.0%), ASA only (6.5%), ASA + enoxaparin (3.6%), enoxaparin only (34.5%), and warfarin only (1.4%). Overall rates of thrombotic, thromboembolic, and mortality events across prophylactic regimens following SCPA were 28.0%, 2.9%, and 9.0%, respectively ([Table 3](#table3-1076029617739702){ref-type="table"}).^[@bibr14-1076029617739702]^ The study reported a decreased risk of thrombotic complications postoperatively with enoxaparin compared to no prophylaxis (hazard ratio \[HR\] = 0.2; *P* = .04). The study found that use of prophylaxis after postoperative day 7 was associated with a lower risk of thrombotic complications and that premature birth (HR = 2.6; 1.1-6.0; *P* = .03) and postoperative extracorporeal membrane oxygenation (HR = 12.5; 3.0-21.7; *P* \< .001) were most associated with increased risk of thrombotic complications postoperatively.^[@bibr14-1076029617739702]^

###### 

Postoperative Thrombotic Complications, Thromboembolic Complications, and Mortality Across Included Studies.

![](10.1177_1076029617739702-table3)

  Author                                          Year   Sample size                        Procedure                                                                  Prophylaxis                                                                                                                                                                                                                    Duration of Follow-Up, Mean, months             Thrombosis, n (%)   Strokes and Pulmonary Embolisms, n (%)                           Major Bleeding, n (%)   Mortality, n (%)
  ----------------------------------------------- ------ ---------------------------------- -------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ----------------------------------------------- ------------------- ---------------------------------------------------------------- ----------------------- --------------------------------------------------
  Douville et al^[@bibr7-1076029617739702]\ ,a^   1991   14                                 Hemi-Fontan^a^                                                             --                                                                                                                                                                                                                             --                                              1 (7.1%)            1 (7.1%)                                                         --                      1 (7.1%)
  Bradley et al^[@bibr8-1076029617739702]\ ,a^    1996   85                                 BDG (n = 33), BDG with intra-atrial patch (n = 14); hemi-Fontan (n = 38)   Prior to PE events: none (n = 43)^b^; following PE events: heparin and ASA (n = 42)^b^                                                                                                                                         23 (13)                                         --                  No prophylaxis: 3 (7.0%); after prophylaxis initiation: 0 (0%)   --                      5 (5.9%)
  Chun et al^[@bibr9-1076029617739702]^           2004   71                                 Hemi-Fontan                                                                ASA and warfarin                                                                                                                                                                                                               --                                              0 (0%)              4 (5.6%)                                                         --                      --
  Day et al^[@bibr10-1076029617739702]\ ,a^       2006   177                                BDG                                                                        Warfarin^c^                                                                                                                                                                                                                    --                                              --                  5 (2.8%)                                                         0 (0%)                  14 (7.9%)
  Procelewska et al^[@bibr11-1076029617739702]^   2007   43                                 Hemi-Fontan                                                                ASA (2-5 mg/kg/d)                                                                                                                                                                                                              --                                              --                  0 (0%)                                                           --                      --
  Honjo et al^[@bibr12-1076029617739702]^         2010   61                                 BDG/hemi-Fontan^d^                                                         BDG: None^d^; V-shaped/hemi-Fontan: initial heparin, then LMWH (85%; 1 mg/kg/d) or ASA (15%)^d^                                                                                                                                --                                              --                  BDG: 3 (8.1%); V-shaped/hemi- Fontan: 1 (4.2%)                   --                      BDG: 9 (24.3%); V-shaped/hemi- Fontan: 3 (12.5%)
  Hansen et al^[@bibr13-1076029617739702]\ ,a^    2011   119                                Hemi-Fontan (n = 113); bilateral BDG (n = 6)^a^                            Initial heparin: 100 IU/kg/d^a^; long-term ASA: 3 mg/kg/d^a^                                                                                                                                                                   17 (5-148)^c,d^                                 5 (4.2%)^a^         5 (4.2%)^a^                                                      --                      12 (10.1%)^a,e^
  Manlhiot et al^[@bibr14-1076029617739702]^      2012   139                                BDG                                                                        Different strategies: none, ASA only, ASA + enoxaparin, enoxaparin only, or warfarin.^f^ For bilateral BDG shunts and high-risk cases: enoxaparin.^g^ Enoxaparin: 1.5 mg/kg/d for age \<2 months, 1.0 mg/kg/d for noninfants   \-^h^                                           39 (28.0%)          4 (2.9%)                                                         4 (2.9%)                12 (8.6%)
  Hansen et al^[@bibr15-1076029617739702]\ ,a^    2013   32                                 Hemi-Fontan^a^                                                             Initial heparin: 100 IU/kg/d^a^; long-term ASA: 3 mg/kg/d^a^                                                                                                                                                                   --                                              --                  4 (12.5%)                                                        --                      1 (3.1%)
  Zampi et al^[@bibr16-1076029617739702]\ ,a^     2013   244                                Hemi-Fontan                                                                ASA (n = 244), heparin (patients with known clot or low flow state). Heparin bridged to enoxaparin (patients with femoral venous or arterial occlusion)                                                                        10 (0.1-65)^c^                                  3 (1.2%)^i^         --                                                               --                      \-^a^
  Ando et al^[@bibr17-1076029617739702]\ ,a^      2014   40 (27 unilateral, 13 bilateral)   BDG                                                                        Unilateral: heparin (n = 9), warfarin (n = 15), ASA (n = 26). Bilateral: heparin (n = 6), warfarin (n = 6), ASA (n = 12). Heparin: 200-400 U/kg/d, ASA: 1 mg/kg/d, warfarin: for INR of 1.5                                    Unilateral: 63 (24)^a^; bilateral: 59 (36)^a^   0 (0%)              0 (0%)^a^                                                        1 (2.5%)                Unilateral: 0 (0%); bilateral: 1 (7.7%)
  Ji et al^[@bibr18-1076029617739702]^            2014   20                                 BDG^d^                                                                     --                                                                                                                                                                                                                             \-^f^                                           1 (5.0%)^g^         --                                                               --                      --
  Zahr et al^[@bibr19-1076029617739702]^          2016   91                                 Hemi-Fontan (n = 89), BDG (n = 2)                                          None                                                                                                                                                                                                                           --                                              0 (0%)              2 (2.2%)^j^                                                      --                      46 (50.5%)^k^

Abbreviations: ASA, acetylsalicylic acid; BDG, bidirectional Glenn; INR, international normalized ratio; LSVC, left superior vena cava; LMWH, low-molecular-weight heparin.

^a^Study authors confirmed accuracy of the extracted data and provided additional data where applicable.

^b^This prophylaxis was only instituted after 3 episodes of pulmonary artery thrombosis had occurred and was only used in 42 patients.

^c^Median (range) reported.

^d^Postoperative hospital stay is reported, not overall duration of follow-up.

^e^Early mortality was reported in 4 (3.4%) of 119; late mortality was reported in 8 (7.0%) of 115.

^f^Angiograms occurred 6 to 12 months postsurgery.

^g^Thrombosis in LSVC as well as the proximal part of left internal jugular vein and left subclavian vein.

^h^Duration of hospital stay was 9 (4-140) months.

^i^Clinically significant thrombus identified requiring cardiac catheterization.

^j^Only strokes explicitly reported. "Pulmonary complications" reported in this study, but not explicitly identified as pulmonary embolic events.

^k^Seven early deaths and 39 late deaths were reported.

Discussion {#section10-1076029617739702}
==========

Postoperative thrombotic and thromboembolic complications have been previously reported to be infrequent.^[@bibr4-1076029617739702]^ However, it is evident from the findings of our literature review that notable variability exists in both reported incidences of thrombosis and thromboembolic events and thromboprophylactic protocols used, with some studies reporting relatively high incidences of such complications despite prophylaxis.

The *American College of Chest Physicians Evidence-Based Clinical Practice Guidelines for Antithrombotic Therapy and the Prevention of Thrombosis* (9th ed.) recommends that neonates and children undergoing the BDG or bilateral cavopulmonary shunt procedure should receive postoperative UFH therapy (grade 2C).^[@bibr4-1076029617739702]^ Despite noting that thrombotic complications are infrequent, the guideline indicates that the completion of the Fontan procedure in many patients suggests a prophylaxis protocol may be beneficial to reduce subsequent risk of thromboembolic events.^[@bibr4-1076029617739702]^

Our findings suggest that thromboprophylaxis protocols vary across institutions and studies, among UFH and ASA, ASA and warfarin, ASA and LMWH, UFH and LMWH, single-agent UFH/warfarin/LMWH/ASA, or a no-thromboprophylaxis protocol postoperatively. While several studies reported on postoperative UFH use, they largely involved UFH as part of a protocol with other medications, and none reported outcome data specifically pertaining to UFH use alone.

In general, incidence of thrombotic and thromboembolic events ranged from 0% to 28.0% and 0% to 12.5% between studies, respectively. Mortality rates ranged from 2.5% to 50.5%. Due to the substantial variability in estimates with each postoperative thromboprophylaxis protocol and no robust studies supporting any single protocol, no clear relationship was identified between protocols and reduction in thrombosis and thromboembolic events.

It is important to recognize the potential risk of bleeding complications with thromboprophylaxis use. Several studies have demonstrated a relatively low overall incidence of these complications in pediatric patients.^[@bibr20-1076029617739702][@bibr21-1076029617739702]--[@bibr22-1076029617739702]^ Only 3 included studies reported the incidence of major bleeding or bleeding requiring reintervention; all consistently reported low rates of such events.^[@bibr10-1076029617739702],[@bibr17-1076029617739702],[@bibr20-1076029617739702]^

It is also important to recognize that all included studies recruited patients prior to the release of the American College of Chest Physicians' guideline recommendations.^[@bibr4-1076029617739702]^ As such, the penetration of these recommendations into clinical practice is challenging to assess based on our findings.

Our findings must be interpreted with several other limitations in mind. While the review is a comprehensive effort to evaluate the risk of thrombosis and thromboembolic complications and the postoperative thromboprophylaxis protocol used in this patient population, the lack of a meta-analysis limits the utility of our findings. Furthermore, while risk of bias wasn't formally assessed, the retrospective nature, small sample sizes and poor reporting quality for outcomes of interest in the majority of studies limit the reliability of the review's findings. The wide variability in study results further limits the generalizability of the findings. In addition, reported rates of thrombotic and thromboembolic complications may be underestimated, given that the majority of the studies included likely reported clinically relevant thrombotic complications. Lastly, several studies report pooled outcome data for patients with different thromboprophylactic protocols, preventing a clear assessment of which protocols were associated with the reported outcome events.

Conclusion {#section11-1076029617739702}
==========

The incidence of thrombotic and thromboembolic complications following initial palliation for pediatric patients with single-ventricle physiology varies from 0% to 28.0% and 12.5%, respectively. They are accompanied by a relatively minor risk of bleeding events. While these thrombotic events have been reportedly infrequent and recent guidance suggests postoperative UFH as a standard prophylactic strategy, significant variance appears to exist in reported incidences of these complications as well as thromboprophylaxis protocols in use.

Our findings highlight the lack of a standardly used thromboprophylaxis protocol based on existing evidence despite existing guidelines. Randomized trials examining thromboprophylaxis protocols are warranted, alongside increased efforts to promote the adoption of a standard protocol for the postoperative management of these patients.
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Database: Ovid MEDLINE(R) In-Process and Other Nonindexed Citations and Ovid MEDLINE(R) \<1946 to Present\> {#section12-1076029617739702}
===========================================================================================================

Search strategy {#section13-1076029617739702}
---------------

1.  BDG.tw. (217)

2.  stage 2 palliation.af. (39)

3.  stage two palliation.af. (1)

4.  Hemi-Fontan.af. (105)

5.  (superior cavopulmonary adj3 (shunt\* or connection or anastomosis or conduit\*)).af. (144)

6.  (bidirectional cavopulmonary adj3 (shunt\* or connection or anastomosis or conduit\*)).af. (347)

7.  Bidirectional Glenn\*.af. (459)

8.  exp Fontan procedure/ (2478)

9.  hypoplastic left heart\*.af. (2783)

10. exp hypoplastic left heart syndrome/ (1718)

11. hlhs.af. (638)

12. or/1-11 (5598)

13. exp Thromboembolism/ (45486)

14. exp Blood Coagulation/ (50338)

15. exp Anticoagulants/ (181827)

16. anticoagul\*.af. (95306)

17. anti-coagul\*.af. (1957)

18. thrombo\*.af. (397787)

19. DVT.tw. (7095)

20. VTE.tw. (5918)

21. emboli\*.af. (129683)

22. clot\*.tw. (51274)

23. or/13-22 (662431)

24. 12 and 23 (490)

25. limit 24 to (\"all infant (birth to 23 months)' or 'all child (0 to 18 years)\") (393)

26. limit 24 to 'all adult (19 plus years)' (122)

27. 24 not 26 (368)

28. 25 or 27 (450)\*

Database: Embase \<1974 to 2017 August 5\> {#section14-1076029617739702}
==========================================

Search strategy {#section15-1076029617739702}
---------------

1.  BDG.tw. (333)

2.  stage 2 palliation.af. (51)

3.  stage two palliation.af. (4)

4.  Hemi-Fontan.af. (135)

5.  (superior cavopulmonary adj3 (shunt\* or connection or anastomosis or conduit\*)).af. (193)

6.  (bidirectional cavopulmonary adj3 (shunt\* or connection or anastomosis or conduit\*)).af. (436)

7.  Bidirectional Glenn\*.af. (666)

8.  exp Fontan procedure/(4497)

9.  exp cavopulmonary connection/(1087)

10. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 (5946)

11. hypoplastic left heart\*.af. (4625)

12. exp hypoplastic left heart syndrome/(3957)

13. hlhs.af. (1158)

14. 11 or 12 or 13 (4765)

15. su.fs. (1782651)

16. exp postoperative complication/(513243)

17. surg\*.tw. (1863056)

18. exp surgery/(3654403)

19. 15 or 16 or 17 or 18 (4560420)

20. 14 and 19 (3473)

21. 10 or 20 (8491)

22. thrombo\*.af. (735912)

23. exp thromboembolism/(370401)

24. exp anticoagulant agent/(520859)

25. anti-coagul\*.af. (3716)

26. anticoagula\*.af. (163467)

27. anticoagula\*.af. (163467)

28. DVT.tw. (12299)

29. VTE.tw. (10826)

30. embo\*.tw. (146334)

31. exp blood clotting/(183498)

32. clot\*.tw. (68638)

33. or/22-32 (1270079)

34. 21 and 33 (1404)

35. limit 34 to (child \<unspecified age\> or preschool child \<1 to 6 years\> or school child \<7 to 12 years\>) (582)

36. limit 34 to adult \<18 to 64 years\> (350)

37. 34 not 36 (1054)

38. 35 or 37 (1200)

39. limit 38 to english language (1152)

40. limit 39 to (conference abstract or conference paper or conference proceeding or note or short survey or trade journal) (245)

41. 39 not 40 (907)

42. from 41 keep 1-907 (907)

Data Extraction Form {#section16-1076029617739702}
====================

![](10.1177_1076029617739702-table4)

  Field                                                 Data
  ----------------------------------------------------- ------
  General study information                             
   Author                                               
   Year of publication                                  
  Study methods                                         
   Procedure of interest^a^                             
   Description of procedure                             
   Sample size                                          
   Recruitment period (\[year\]-\[year\])               
  Demographics                                          
   Age, mean (SD)                                       
   Male, n (%)                                          
   Female, n (%)                                        
   Weight, mean (SD), kg                                
   Relevant comorbidities/associated complications      
  Prophylaxis measures                                  
   Main prophylactic medication type                    
   Proportion of sample receiving prophylaxis           
   Other prophylaxis provided                           
   Description of which patients received prophylaxis   
   Dose of prophylaxis                                  
   Frequency of prophylaxis administration              
   Duration of prophylaxis, days                        
  Duration of follow-up                                 
   Measure (mean/median/mode)                           
   Duration of primary outcome follow-up, days          
  Outcome: thrombotic events                            
   Definition of thrombotic events                      
   Incidence of thrombotic events                       
   Patients with thrombotic events, number (%)          
   Sample assessed for outcome                          
  Outcome: thromboembolic events                        
   Definition of thromboembolic events                  
   Incidence of thromboembolic events                   
   Patients with thromboembolic events, number (%)      
   Sample assessed for outcome                          
  Outcome: major bleeding events                        
   Definition of major bleeding events                  
   Incidence of major bleeding events                   
   Patients with major bleeding events, number (%)      
   Sample assessed for outcome                          
  Outcome: mortality                                    
   Incidence of mortality events                        
   Patients with thrombotic events, number (%)          
   Sample assessed for outcome                          

Abbreviation: SD, standard deviation.

^a^If more than 1 procedure of interest was reported in a study, data were extracted separately for each procedure of interest.
